ID   RYK_HUMAN               Reviewed;         607 AA.
AC   P34925; A0A087WUK1; A0A096LNL3; Q04696;
DT   01-FEB-1994, integrated into UniProtKB/Swiss-Prot.
DT   28-MAR-2018, sequence version 3.
DT   12-OCT-2022, entry version 199.
DE   RecName: Full=Tyrosine-protein kinase RYK {ECO:0000305};
DE            EC=2.7.10.1 {ECO:0000255|PROSITE-ProRule:PRU00159};
DE   Flags: Precursor;
GN   Name=RYK {ECO:0000312|HGNC:HGNC:10481}; Synonyms=JTK5A;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT ASN-99.
RX   PubMed=8386829;
RA   Stacker S.A., Hovens C.M., Vitali A., Pritchard M.A., Baker E.,
RA   Sutherland G.R., Wilks A.F.;
RT   "Molecular cloning and chromosomal localisation of the human homologue of a
RT   receptor related to tyrosine kinases (RYK).";
RL   Oncogene 8:1347-1356(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), AND VARIANT ASN-99.
RX   PubMed=8390040;
RA   Tamagnone L., Partanen J., Armstrong E., Lasota J., Ohgami K., Tazunoki T.,
RA   Laforgia S., Huebner K., Alitalo K.;
RT   "The human ryk cDNA sequence predicts a protein containing two putative
RT   transmembrane segments and a tyrosine kinase catalytic domain.";
RL   Oncogene 8:2009-2014(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16641997; DOI=10.1038/nature04728;
RA   Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R., Buhay C.J.,
RA   Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R., Gunaratne P.,
RA   Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V., Hume J., Jackson A.,
RA   Khan Z.M., Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L.,
RA   Milosavljevic A., Miner G.R., Morgan M.B., Nazareth L.V., Scott G.,
RA   Sodergren E., Song X.-Z., Steffen D., Wei S., Wheeler D.A., Wright M.W.,
RA   Worley K.C., Yuan Y., Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M.,
RA   Brown M.J., Chen G., Chen Z., Clendenning J., Clerc-Blankenburg K.P.,
RA   Chen R., Chen Z., Davis C., Delgado O., Dinh H.H., Dong W., Draper H.,
RA   Ernst S., Fu G., Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J.,
RA   Hao B., Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W.,
RA   Jackson L.R., Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B.,
RA   Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O.,
RA   Palmeiri A., Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B.,
RA   Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H.,
RA   Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J.,
RA   Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J., Zhang X.,
RA   Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H., Reinhardt R.,
RA   Naylor S.L., Yang H., Olson M., Weinstock G., Gibbs R.A.;
RT   "The DNA sequence, annotation and analysis of human chromosome 3.";
RL   Nature 440:1194-1198(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 46-607 (ISOFORM 1), AND VARIANT ASN-99.
RC   TISSUE=Ovary;
RX   PubMed=8726462; DOI=10.1007/bf03401616;
RA   Wang X.C., Katso R., Butler R., Hanby A.M., Poulsom R., Jones T., Sheer D.,
RA   Ganesan T.S.;
RT   "H-RYK, an unusual receptor kinase: isolation and analysis of expression in
RT   ovarian cancer.";
RL   Mol. Med. 2:189-203(1996).
RN   [5]
RP   MUTAGENESIS OF LYS-364; ASN-484 AND ALA-485.
RX   PubMed=10454588; DOI=10.1128/mcb.19.9.6427;
RA   Katso R.M., Russell R.B., Ganesan T.S.;
RT   "Functional analysis of H-Ryk, an atypical member of the receptor tyrosine
RT   kinase family.";
RL   Mol. Cell. Biol. 19:6427-6440(1999).
RN   [6]
RP   FUNCTION, AND INTERACTION WITH DVL1.
RX   PubMed=15454084; DOI=10.1016/j.cell.2004.09.019;
RA   Lu W., Yamamoto V., Ortega B., Baltimore D.;
RT   "Mammalian Ryk is a Wnt coreceptor required for stimulation of neurite
RT   outgrowth.";
RL   Cell 119:97-108(2004).
RN   [7]
RP   CLEAVAGE BY PRESENILIN.
RX   PubMed=16116452; DOI=10.1038/nn1520;
RA   Liu Y., Shi J., Lu C.C., Wang Z.B., Lyuksyutova A.I., Song X.J., Zou Y.;
RT   "Ryk-mediated Wnt repulsion regulates posterior-directed growth of
RT   corticospinal tract.";
RL   Nat. Neurosci. 8:1151-1159(2005).
RN   [8]
RP   VARIANTS [LARGE SCALE ANALYSIS] ASN-99; CYS-227 AND ILE-243.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: May be a coreceptor along with FZD8 of Wnt proteins, such as
CC       WNT1, WNT3, WNT3A and WNT5A. Involved in neuron differentiation, axon
CC       guidance, corpus callosum establishment and neurite outgrowth. In
CC       response to WNT3 stimulation, receptor C-terminal cleavage occurs in
CC       its transmembrane region and allows the C-terminal intracellular
CC       product to translocate from the cytoplasm to the nucleus where it plays
CC       a crucial role in neuronal development. {ECO:0000269|PubMed:15454084}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-
CC         [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.10.1;
CC         Evidence={ECO:0000255|PROSITE-ProRule:PRU10028};
CC   -!- SUBUNIT: Interacts with DVL1 (via PDZ domain).
CC       {ECO:0000269|PubMed:15454084}.
CC   -!- SUBCELLULAR LOCATION: Membrane {ECO:0000250}; Single-pass type I
CC       membrane protein {ECO:0000250}. Nucleus {ECO:0000250}. Cytoplasm
CC       {ECO:0000250}. Note=In cells that have undergone neuronal
CC       differentiation, the C-terminal cleaved part is translocated from the
CC       cytoplasm to the nucleus. {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P34925-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P34925-2; Sequence=VSP_005009;
CC   -!- TISSUE SPECIFICITY: Observed in all the tissues examined.
CC   -!- DOMAIN: The extracellular WIF domain is responsible for Wnt binding.
CC       {ECO:0000250}.
CC   -!- PTM: Proteolytically cleaved, in part by presenilin, in response to
CC       WNT3 stimulation. Cleavage occurs during neuronal differentiation.
CC       {ECO:0000269|PubMed:16116452}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- CAUTION: According to some authors, has impaired kinase activity.
CC       {ECO:0000305|PubMed:10454588}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAB26341.1; Type=Frameshift; Evidence={ECO:0000305};
CC       Sequence=CAA65406.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; S59184; AAB26341.1; ALT_FRAME; mRNA.
DR   EMBL; X69970; CAA49591.1; -; mRNA.
DR   EMBL; AC096967; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC107310; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC108742; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AMYH02007719; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; X96588; CAA65406.1; ALT_INIT; mRNA.
DR   CCDS; CCDS75016.1; -. [P34925-2]
DR   CCDS; CCDS77820.1; -. [P34925-1]
DR   PIR; I37560; I37560.
DR   RefSeq; NP_001005861.1; NM_001005861.2. [P34925-2]
DR   RefSeq; NP_002949.2; NM_002958.3. [P34925-1]
DR   PDB; 6TUA; X-ray; 2.38 A; A=293-607.
DR   PDBsum; 6TUA; -.
DR   AlphaFoldDB; P34925; -.
DR   SMR; P34925; -.
DR   BioGRID; 112171; 174.
DR   IntAct; P34925; 67.
DR   MINT; P34925; -.
DR   STRING; 9606.ENSP00000478721; -.
DR   GlyGen; P34925; 5 sites.
DR   PhosphoSitePlus; P34925; -.
DR   BioMuta; RYK; -.
DR   DMDM; 1710811; -.
DR   MassIVE; P34925; -.
DR   PaxDb; P34925; -.
DR   PeptideAtlas; P34925; -.
DR   PRIDE; P34925; -.
DR   ProteomicsDB; 54954; -. [P34925-1]
DR   ProteomicsDB; 54955; -. [P34925-2]
DR   Antibodypedia; 33387; 407 antibodies from 32 providers.
DR   CPTC; P34925; 3 antibodies.
DR   DNASU; 6259; -.
DR   Ensembl; ENST00000620660.4; ENSP00000478721.1; ENSG00000163785.13. [P34925-2]
DR   Ensembl; ENST00000623711.4; ENSP00000485095.1; ENSG00000163785.13. [P34925-1]
DR   GeneID; 6259; -.
DR   KEGG; hsa:6259; -.
DR   MANE-Select; ENST00000623711.4; ENSP00000485095.1; NM_002958.4; NP_002949.2.
DR   CTD; 6259; -.
DR   DisGeNET; 6259; -.
DR   GeneCards; RYK; -.
DR   HGNC; HGNC:10481; RYK.
DR   HPA; ENSG00000163785; Low tissue specificity.
DR   MIM; 600524; gene.
DR   neXtProt; NX_P34925; -.
DR   OpenTargets; ENSG00000163785; -.
DR   PharmGKB; PA34894; -.
DR   VEuPathDB; HostDB:ENSG00000163785; -.
DR   eggNOG; KOG1024; Eukaryota.
DR   GeneTree; ENSGT00940000155119; -.
DR   InParanoid; P34925; -.
DR   OMA; NTRNLKQ; -.
DR   PhylomeDB; P34925; -.
DR   TreeFam; TF317402; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   PathwayCommons; P34925; -.
DR   Reactome; R-HSA-201681; TCF dependent signaling in response to WNT.
DR   Reactome; R-HSA-4086400; PCP/CE pathway.
DR   SignaLink; P34925; -.
DR   SIGNOR; P34925; -.
DR   BioGRID-ORCS; 6259; 15 hits in 284 CRISPR screens.
DR   ChiTaRS; RYK; human.
DR   GeneWiki; Related_to_receptor_tyrosine_kinase; -.
DR   GenomeRNAi; 6259; -.
DR   Pharos; P34925; Tbio.
DR   PRO; PR:P34925; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   RNAct; P34925; protein.
DR   Bgee; ENSG00000163785; Expressed in buccal mucosa cell and 213 other tissues.
DR   ExpressionAtlas; P34925; baseline and differential.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0016021; C:integral component of membrane; NAS:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; IBA:GO_Central.
DR   GO; GO:0016020; C:membrane; ISS:UniProtKB.
DR   GO; GO:0005634; C:nucleus; ISS:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0043235; C:receptor complex; IBA:GO_Central.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:1904929; F:coreceptor activity involved in Wnt signaling pathway, planar cell polarity pathway; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0005109; F:frizzled binding; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0004672; F:protein kinase activity; IEA:InterPro.
DR   GO; GO:0004888; F:transmembrane signaling receptor activity; IDA:UniProtKB.
DR   GO; GO:0042813; F:Wnt receptor activity; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0017147; F:Wnt-protein binding; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0048846; P:axon extension involved in axon guidance; IEA:Ensembl.
DR   GO; GO:0007411; P:axon guidance; ISS:UniProtKB.
DR   GO; GO:0007409; P:axonogenesis; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0060070; P:canonical Wnt signaling pathway; NAS:ParkinsonsUK-UCL.
DR   GO; GO:0033278; P:cell proliferation in midbrain; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0036518; P:chemorepulsion of dopaminergic neuron axon; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0071679; P:commissural neuron axon guidance; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0022038; P:corpus callosum development; ISS:UniProtKB.
DR   GO; GO:1904948; P:midbrain dopaminergic neuron differentiation; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0048843; P:negative regulation of axon extension involved in axon guidance; IEA:Ensembl.
DR   GO; GO:0022008; P:neurogenesis; NAS:ParkinsonsUK-UCL.
DR   GO; GO:0030182; P:neuron differentiation; ISS:UniProtKB.
DR   GO; GO:0031175; P:neuron projection development; ISS:UniProtKB.
DR   GO; GO:0035567; P:non-canonical Wnt signaling pathway; NAS:ParkinsonsUK-UCL.
DR   GO; GO:0016310; P:phosphorylation; IEA:UniProtKB-KW.
DR   GO; GO:1904938; P:planar cell polarity pathway involved in axon guidance; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0033674; P:positive regulation of kinase activity; IBA:GO_Central.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; IDA:UniProtKB.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0048705; P:skeletal system morphogenesis; IEA:Ensembl.
DR   GO; GO:0007416; P:synapse assembly; NAS:ParkinsonsUK-UCL.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IBA:GO_Central.
DR   GO; GO:1904953; P:Wnt signaling pathway involved in midbrain dopaminergic neuron differentiation; ISS:ParkinsonsUK-UCL.
DR   Gene3D; 2.60.40.2170; -; 1.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR003306; WIF.
DR   InterPro; IPR038677; WIF_sf.
DR   Pfam; PF07714; PK_Tyr_Ser-Thr; 1.
DR   Pfam; PF02019; WIF; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00469; WIF; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS50814; WIF; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cytoplasm; Disulfide bond;
KW   Glycoprotein; Kinase; Membrane; Nucleotide-binding; Nucleus;
KW   Phosphoprotein; Receptor; Reference proteome; Signal; Transferase;
KW   Transmembrane; Transmembrane helix; Tyrosine-protein kinase;
KW   Wnt signaling pathway.
FT   SIGNAL          1..25
FT                   /evidence="ECO:0000255"
FT   CHAIN           26..607
FT                   /note="Tyrosine-protein kinase RYK"
FT                   /id="PRO_0000024464"
FT   TOPO_DOM        26..227
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        228..248
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        249..607
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          66..194
FT                   /note="WIF"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00222"
FT   DOMAIN          330..603
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          1..20
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          266..290
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        465
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         336..344
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         364
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         495
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000250"
FT   CARBOHYD        139
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        174
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        178
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        182
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        209
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        159..194
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00222"
FT   VAR_SEQ         297
FT                   /note="S -> SSLG (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:8390040"
FT                   /id="VSP_005009"
FT   VARIANT         99
FT                   /note="S -> N (in dbSNP:rs1131262)"
FT                   /evidence="ECO:0000269|PubMed:17344846,
FT                   ECO:0000269|PubMed:8386829, ECO:0000269|PubMed:8390040,
FT                   ECO:0000269|PubMed:8726462"
FT                   /id="VAR_041800"
FT   VARIANT         227
FT                   /note="R -> C (in dbSNP:rs55740278)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041801"
FT   VARIANT         243
FT                   /note="V -> I (in an ovarian mucinous carcinoma sample;
FT                   somatic mutation; dbSNP:rs746238409)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041802"
FT   MUTAGEN         364
FT                   /note="K->A: No induction of the MAPK pathway."
FT                   /evidence="ECO:0000269|PubMed:10454588"
FT   MUTAGEN         484
FT                   /note="N->F: Gain of an autophosphorylation activity. Gain
FT                   of an autophosphorylation activity; when associated with
FT                   A-359. Gain of an autophosphorylation activity; when
FT                   associated with G-334 and G-482."
FT                   /evidence="ECO:0000269|PubMed:10454588"
FT   MUTAGEN         485
FT                   /note="A->G: Gain of an autophosphorylation activity. Gain
FT                   of an autophosphorylation activity; when associated with
FT                   G-334 and F-481."
FT                   /evidence="ECO:0000269|PubMed:10454588"
FT   CONFLICT        26
FT                   /note="P -> R (in Ref. 1; AAB26341)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        33
FT                   /note="L -> V (in Ref. 1; AAB26341)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        254
FT                   /note="S -> N (in Ref. 1; AAB26341 and 4; CAA65406)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        319
FT                   /note="K -> E (in Ref. 2; CAA49591)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        358
FT                   /note="E -> K (in Ref. 4; CAA65406)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        440
FT                   /note="Q -> H (in Ref. 2; CAA49591)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        446
FT                   /note="A -> P (in Ref. 2; CAA49591)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        531
FT                   /note="T -> NS (in Ref. 1; AAB26341)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        544
FT                   /note="V -> TL (in Ref. 1; AAB26341)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        566
FT                   /note="N -> T (in Ref. 1; AAB26341)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        588
FT                   /note="K -> R (in Ref. 1; AAB26341)"
FT                   /evidence="ECO:0000305"
FT   HELIX           313..319
FT                   /evidence="ECO:0007829|PDB:6TUA"
FT   HELIX           320..323
FT                   /evidence="ECO:0007829|PDB:6TUA"
FT   HELIX           327..329
FT                   /evidence="ECO:0007829|PDB:6TUA"
FT   STRAND          330..338
FT                   /evidence="ECO:0007829|PDB:6TUA"
FT   STRAND          340..349
FT                   /evidence="ECO:0007829|PDB:6TUA"
FT   STRAND          359..366
FT                   /evidence="ECO:0007829|PDB:6TUA"
FT   HELIX           372..382
FT                   /evidence="ECO:0007829|PDB:6TUA"
FT   TURN            383..387
FT                   /evidence="ECO:0007829|PDB:6TUA"
FT   STRAND          398..400
FT                   /evidence="ECO:0007829|PDB:6TUA"
FT   STRAND          408..412
FT                   /evidence="ECO:0007829|PDB:6TUA"
FT   HELIX           419..432
FT                   /evidence="ECO:0007829|PDB:6TUA"
FT   HELIX           434..436
FT                   /evidence="ECO:0007829|PDB:6TUA"
FT   HELIX           439..458
FT                   /evidence="ECO:0007829|PDB:6TUA"
FT   HELIX           468..470
FT                   /evidence="ECO:0007829|PDB:6TUA"
FT   STRAND          471..473
FT                   /evidence="ECO:0007829|PDB:6TUA"
FT   STRAND          479..481
FT                   /evidence="ECO:0007829|PDB:6TUA"
FT   HELIX           487..490
FT                   /evidence="ECO:0007829|PDB:6TUA"
FT   HELIX           492..494
FT                   /evidence="ECO:0007829|PDB:6TUA"
FT   HELIX           506..508
FT                   /evidence="ECO:0007829|PDB:6TUA"
FT   HELIX           511..516
FT                   /evidence="ECO:0007829|PDB:6TUA"
FT   HELIX           521..536
FT                   /evidence="ECO:0007829|PDB:6TUA"
FT   TURN            542..545
FT                   /evidence="ECO:0007829|PDB:6TUA"
FT   HELIX           548..550
FT                   /evidence="ECO:0007829|PDB:6TUA"
FT   HELIX           551..556
FT                   /evidence="ECO:0007829|PDB:6TUA"
FT   HELIX           569..578
FT                   /evidence="ECO:0007829|PDB:6TUA"
FT   HELIX           583..585
FT                   /evidence="ECO:0007829|PDB:6TUA"
FT   HELIX           589..605
FT                   /evidence="ECO:0007829|PDB:6TUA"
SQ   SEQUENCE   607 AA;  67815 MW;  3AFAE21A2680F400 CRC64;
     MRGAARLGRP GRSCLPGARG LRAPPPPPLL LLLALLPLLP APGAAAAPAP RPPELQSASA
     GPSVSLYLSE DEVRRLIGLD AELYYVRNDL ISHYALSFSL LVPSETNFLH FTWHAKSKVE
     YKLGFQVDNV LAMDMPQVNI SVQGEVPRTL SVFRVELSCT GKVDSEVMIL MQLNLTVNSS
     KNFTVLNFKR RKMCYKKLEE VKTSALDKNT SRTIYDPVHA APTTSTRVFY ISVGVCCAVI
     FLVAIILAVL HLHSMKRIEL DDSISASSSS QGLSQPSTQT TQYLRADTPN NATPITSYPT
     LRIEKNDLRS VTLLEAKGKV KDIAISRERI TLKDVLQEGT FGRIFHGILI DEKDPNKEKQ
     AFVKTVKDQA SEIQVTMMLT ESCKLRGLHH RNLLPITHVC IEEGEKPMVI LPYMNWGNLK
     LFLRQCKLVE ANNPQAISQQ DLVHMAIQIA CGMSYLARRE VIHKDLAARN CVIDDTLQVK
     ITDNALSRDL FPMDYHCLGD NENRPVRWMA LESLVNNEFS SASDVWAFGV TLWELMTLGQ
     TPYVDIDPFE MAAYLKDGYR IAQPINCPDE LFAVMACCWA LDPEERPKFQ QLVQCLTEFH
     AALGAYV
//
